Impact of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients

NCT00999258

Last updated date
Study Location
Temple University
Philadelphia, Pennsylvania, 19140, United States
Contact
215-707-9171

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

215-707-9171

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Glomerular Filtration Rate, Chronic Allograft Nephropathy
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- African American (self-identified) renal transplant recipients.

- Primary or re-transplant kidney-only recipients.

- Recipients on tacrolimus-based immunosuppression regimen.

- Time interval after transplant: at least 3 months but not greater than 5 years.

- Renal transplant recipients with 10% decrease in GFR from baseline.

- Women of childbearing potential must have a negative pregnancy test upon enrollment, and must consent to receive contraceptive counseling and to use effective contraception while enrolled in the study. Two reliable forms of contraception must be used simultaneously unless abstinence is the chosen method.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- GFR <40ml/min.


- Urine protein-to-creatinine ratio >0.5.


- Significant chronic allograft nephropathy grade 3 Banff score.


- Evidence of acute rejection episodes within the past 3 months.


- Evidence of active infection within the past month.


- Any malignancy except treated non-melanoma skin cancer within the past 3 years.


- Leucopenia <2,000/mm3 within the past month.


- Thrombocytopenia <100,000/mm3 within the past month.


- Total cholesterol >300mg/dl, despite adequate treatment.


- Triglycerides >500mg/dl, despite adequate treatment.


- Non-healed post-surgical or non-surgical wound.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Glomerular Filtration Rate, Chronic Allograft NephropathyImpact of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients
NCT00999258
  1. Philadelphia, Pennsylvania
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Impact of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients
Official Title  ICMJE Prospective Trial of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients With Chronic Allograft Nephropathy
Brief Summary

The objective of this study is to examine the effect on allograft function and histology of converting African American renal transplant recipients with chronic allograft nephropathy (CAN) from a tacrolimus-based regimen to a sirolimus-based maintenance immunosuppression regimen.

The investigators hypothesize that the conversion from tacrolimus to sirolimus in African American renal recipients will stabilize or improve renal allograft function, and stabilize the histological progression of CAN. This conversion will have the potential to prolong long-term graft survival in African American renal transplant patients.

GFR measurements, histological parameters on the allograft biopsy, as well as patient and graft survival, incidence of acute rejection, and specific side effects will be monitored and compared between the sirolimus conversion group and the patients who will be maintained on tacrolimus.

Detailed Description

All African American renal transplant recipients (>3months and <5 years post-transplant) at our institution that are currently on a tacrolimus based regimen will be screened. Subjects with 10% or more decrease in glomerular filtration rate (GFR) from baseline, estimated by the MDRD formula,65 and who meet all inclusion criteria will be consented to be enrolled in the study. Baseline will be defined as the highest GFR estimated by MDRD formula, within 3 months of transplant.

Subjects who consent to participate in the study will undergo allograft biopsy and GFR measurement by Gd-DTPA, and will be randomly assigned (2:1) to undergo conversion from tacrolimus to sirolimus or to continue to receive tacrolimus.

The subjects assigned to the sirolimus conversion group will be initiated on sirolimus 5mg po daily at which time their tacrolimus dose will be decreased by 50%. Sirolimus levels will be checked within a week and adjusted in a linear fashion to achieve a trough goal of 12-15ng/ml in subjects within 1 year post-transplant, and 8-12 ng/ml in subjects more than 1 year post-transplant. Tacrolimus will be continued in these subjects until sirolimus target trough levels are achieved. Thereafter, tacrolimus will be discontinued indefinitely. Sirolimus trough levels will be monitored in the study as follows: weekly for the first month, monthly from 1 - 6 months, every 3 months from 6 months - 1 year post conversion. Subjects will continue to receive maintenance immunosuppression consisting of mycophenolate mofetil 500mg to 1000 mg po bid as tolerated and corticosteroid taper per protocol (maintenance of 2.5mg - 5mg po daily at 6 months post-transplant and then indefinitely). GFR measurement by DTPA will be repeated at 6 months, and 1 year post conversion. The second allograft biopsy will be performed at 1 year after sirolimus conversion.

The subjects assigned to the tacrolimus maintenance group (control group) represent our present standard of care. The subjects will continue to receive prednisone, and mycophenolate mofetil, similarly to the subjects assigned to the sirolimus conversion group. In the tacrolimus maintenance group, the subjects will be monitored according to our current clinic protocol, monthly between 3 months - 1 year post transplant, every two months in the second year post-transplant and every 3 months after 2 years. The tacrolimus dose will be adjusted to achieve a trough of 5-10ng/ml in subjects randomized to the control group which is standard of care per protocol. GFR measurement by DTPA will be repeated at 6 months, and 1 year post randomization. The second allograft biopsy will be performed at 1 year post randomization.

Patient and graft survival, and the incidence of acute rejection, proteinuria, hyperlipidemia, anemia, leucopenia, thrombocytopenia, and other clinical parameters will be monitored and compared between the sirolimus conversion group and the subjects who will be maintained on tacrolimus.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Glomerular Filtration Rate
  • Chronic Allograft Nephropathy
Intervention  ICMJE Drug: sirolimus

The subjects assigned to the sirolimus conversion group will be initiated on sirolimus 5mg po daily at which time their tacrolimus dose will be decreased by 50%. Sirolimus levels will be checked within a week and adjusted in a linear fashion to achieve a trough goal of 12-15ng/ml in subjects within 1 year post-transplant, and 8-12 ng/ml in subjects more than 1 year post-transplant. Tacrolimus will be continued in these subjects until sirolimus target trough levels are achieved. Thereafter, tacrolimus will be discontinued indefinitely.

The subjects assigned to the tacrolimus maintenance group (control group) represent our present standard of care.

Other Name: GFR measurements and allograft biopsies
Study Arms  ICMJE
  • Active Comparator: sirolimus
    the subjects will undergo conversion from tacrolimus to sirolimus OR they will continue to receive tacrolimus.
    Intervention: Drug: sirolimus
  • No Intervention: tacrolimus
    Intervention: Drug: sirolimus
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Unknown status
Estimated Enrollment  ICMJE
 (submitted: October 20, 2009)
50
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE June 2011
Estimated Primary Completion Date June 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • African American (self-identified) renal transplant recipients.
  • Primary or re-transplant kidney-only recipients.
  • Recipients on tacrolimus-based immunosuppression regimen.
  • Time interval after transplant: at least 3 months but not greater than 5 years.
  • Renal transplant recipients with 10% decrease in GFR from baseline.
  • Women of childbearing potential must have a negative pregnancy test upon enrollment, and must consent to receive contraceptive counseling and to use effective contraception while enrolled in the study. Two reliable forms of contraception must be used simultaneously unless abstinence is the chosen method.

Exclusion Criteria:

  • GFR <40ml/min.
  • Urine protein-to-creatinine ratio >0.5.
  • Significant chronic allograft nephropathy grade 3 Banff score.
  • Evidence of acute rejection episodes within the past 3 months.
  • Evidence of active infection within the past month.
  • Any malignancy except treated non-melanoma skin cancer within the past 3 years.
  • Leucopenia <2,000/mm3 within the past month.
  • Thrombocytopenia <100,000/mm3 within the past month.
  • Total cholesterol >300mg/dl, despite adequate treatment.
  • Triglycerides >500mg/dl, despite adequate treatment.
  • Non-healed post-surgical or non-surgical wound.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00999258
Other Study ID Numbers  ICMJE 0468X1-4504
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Serban Constantinescu, Temple University
Study Sponsor  ICMJE Temple University
Collaborators  ICMJE Wyeth is now a wholly owned subsidiary of Pfizer
Investigators  ICMJE
Principal Investigator:Serban Constantinescu, MD, PhDTemple University
PRS Account Temple University
Verification Date October 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP